Teva Stock Pops on Generic NuvaRing® Announcement

The equity added 23% in the last three months

Deputy Editor
Jan 15, 2021 at 10:32 AM
facebook twitter linkedin


The shares of Teva Pharmaceutical Industries Ltd (NYSE:TEVA) are up 0.4% at $11.54 this morning, after the company announced plans to launch a generic version of Merck's (MRK) birth control device known as the NuvaRing®. According to data from IQVIA as of November 2020, vaginal ring contraceptives like the one Teva will produce have annual sales of over $837 million in the U.S.

The equity has had a volatile run on the charts of late. After pulling back to $9.65 to close out 2020, TEVA shot up the charts to trade as high as $11.90 by Jan. 13 -- its highest level since August. Over the last three months, the security has added 23%, while its 10-day moving average has already contained at least two pullbacks since the year started.

Meanwhile, the options pits are bullish, as per the security's 50-day call/put volume ratio of 22.17 at the International Securities Exchange (ISE), Cboe Options Exchange (CBOE), and NASDAQ OMX PHLX (PHLX). This ratio stands higher than 99% of readings from the past year, indicating long calls are being picked up at a faster-than-usual clip. 

As far as options are concerned, TEVA's Schaeffer's Volatility Index (SVI) of 56% sits in the low 9th annual percentile. This means low volatility expectations are being priced into near-term contracts -- a boon to potential premium buyers.

 

If you are not making money with options, you aren’t buying options like this…

There is no options strategy that more perfectly approaches trading the fastest moving and most volatile stocks available in the marketplace than this one. In fact, there is no strategy that better utilizes put options for optimal returns and a real trading edge over other traders in the exact same market. New options traders fail out at an incredible rate without proper trade research, execution timing, and option picking. Capitalize on Schaeffer’s 100+ years of options trading excellence with the most coveted product launch in company history. Don't waste another second... join us right now before the next round of trades are released!

SCHAEFFER'S JULY STOCKS REPORT AD
 


 


 
Special Offers from Schaeffer's Trading Partners